Des-acyl ghrelin exhibits pro-anabolic and anti-catabolic effects on C2C12 myotubes exposed to cytokines and reduces burn-induced muscle proteolysis in rats

Mol Cell Endocrinol. 2012 Apr 4;351(2):286-95. doi: 10.1016/j.mce.2011.12.021. Epub 2012 Jan 14.

Abstract

Although ghrelin and GHRP-2 have been shown to inhibit skeletal muscle proteolysis in rats with burn injury, the effects of des-acyl ghrelin (DAG) have not been reported. In this paper, we demonstrate that continuous 24h administration of DAG attenuated burn-induced EDL muscle proteolysis, and normalized elevated TNFα mRNA. Combined treatment of cultured C2C12 myotubes with TNFα and IFN-γ (TNF+IFN) inhibited protein synthesis and increased protein breakdown; DAG abolished both effects. PI3 kinase inhibition by LY294002 and mTOR inhibition by rapamycin blocked the reversal of the anti-anabolic effects of TNF+IFN-treated myotubes by DAG. DAG also reversed or attenuated the TNF+IFN-induced reduction in phosphorylation of Akt, FOXO1, 4E-BP-1, and GSK-3β in myotubes. Furthermore, DAG attenuated the atrophy signal, phospho-NF-κB, and the mRNA expression of MAFbx and MuRF1, upregulated by TNF+IFN in C2C12 myotubes. We conclude that DAG reduces muscle cachexia produced by injury and proinflammatory cytokines, and that DAG or DAG-based compounds may be useful in treating wasting disorders.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Anabolic Agents / pharmacology
  • Animals
  • Burns / metabolism*
  • Burns / pathology
  • Cachexia / drug therapy
  • Carrier Proteins / metabolism
  • Cells, Cultured
  • Chromones / pharmacology
  • Forkhead Transcription Factors / metabolism
  • Ghrelin / pharmacology*
  • Glycogen Synthase Kinase 3 / metabolism
  • Glycogen Synthase Kinase 3 beta
  • Interferon-gamma / pharmacology
  • Intracellular Signaling Peptides and Proteins
  • Mice
  • Morpholines / pharmacology
  • Muscle Fibers, Skeletal / drug effects*
  • Muscle Fibers, Skeletal / metabolism*
  • Muscle Fibers, Skeletal / pathology
  • Muscle Proteins / genetics
  • Muscle, Skeletal / metabolism*
  • Muscle, Skeletal / pathology
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / metabolism
  • Nerve Tissue Proteins / metabolism
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphoproteins / metabolism
  • Phosphorylation / drug effects
  • Protein Biosynthesis / drug effects
  • Proteolysis / drug effects
  • Proto-Oncogene Proteins c-akt / metabolism
  • RNA, Messenger / biosynthesis
  • Rats
  • Rats, Sprague-Dawley
  • SKP Cullin F-Box Protein Ligases / genetics
  • Sirolimus / pharmacology
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • Tripartite Motif Proteins
  • Tumor Necrosis Factor-alpha / biosynthesis
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / pharmacology
  • Ubiquitin-Protein Ligases / genetics

Substances

  • Anabolic Agents
  • Carrier Proteins
  • Chromones
  • Eif4ebp1 protein, rat
  • Forkhead Transcription Factors
  • Ghrelin
  • Intracellular Signaling Peptides and Proteins
  • Morpholines
  • Muscle Proteins
  • NF-kappa B
  • Nerve Tissue Proteins
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphoproteins
  • RNA, Messenger
  • Tripartite Motif Proteins
  • Tumor Necrosis Factor-alpha
  • ghrelin, des-n-octanoyl
  • Foxo1 protein, rat
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Interferon-gamma
  • Fbxo32 protein, rat
  • SKP Cullin F-Box Protein Ligases
  • Trim63 protein, rat
  • Ubiquitin-Protein Ligases
  • mTOR protein, rat
  • Glycogen Synthase Kinase 3 beta
  • Gsk3b protein, mouse
  • Gsk3b protein, rat
  • Proto-Oncogene Proteins c-akt
  • TOR Serine-Threonine Kinases
  • Glycogen Synthase Kinase 3
  • Sirolimus